Locations:
Search IconSearch
October 5, 2020/Cancer

Distance to Treatment Center Impacts Survival in Children and Young Adults With Acute Lymphoblastic Leukemia

Findings of a new study emphasize the importance of psychosocial support for patients and families

650×450-Child-Rural-Cancer

Children and young adults with acute lymphoblastic leukemia (ALL) who live more than 50 miles away from a treatment center face inferior survival outcomes, according to a recent study conducted at Cleveland Clinic Children’s.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“There have been great advances in treatment for leukemia; however, outcomes remain variable,” says Rabi Hanna, MD, Chair of the Department of Pediatric Hematology, Oncology and Bone and Marrow Transplantation at Cleveland Clinic Children’s and co-author of the study. “We embarked upon this analysis in order to identify variables that may impact outcomes, looking for ways we might improve the care and outcomes of these young patients.”

Variables associated with outcomes in ALL and AML

Researchers investigated possible associations with outcomes as related to variables such as time to treatment, treatment at a National Cancer Institute-designated cancer center, Charlson-Deyo score, age, race, insurance status and community income level among children, and adolescent and young adult (AYA) patients with ALL (N = 22,683) and acute myeloid leukemia (AML; N = 12,301) in the National Cancer Database (NCDB).

For ALL, race, insurance, community median income and living more than 50 miles from a treatment center were associated with survival. Specifically, patients who identified as Black, Hispanic/Latino or Native American had inferior survival outcomes compared with those who identified as white. Patients with government insurance or no insurance at the time of diagnosis had inferior survival compared with patients who had private insurance. Additionally, patients living in communities with a median income of ≥ $63,000 had superior outcomes when compared with patients living in communities with lower median incomes.

Among the AML cohort, distance to a treatment center was not associated with survival. Similar to the ALL model, insurance and community median income level were associated with survival. Racial disparities were prevalent in AML as well, as individuals who identified as Black had inferior survival compared with those who identified as white. However, no difference was seen for those who identified as Asian, Hispanic/Latino or Native American compared with patients who identified as white.

Advertisement

Image reused with permission. Originally published in: Rotz SJ, Wei W, Thomas SM, Hanna R. Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia. Cancer. 2020;0:1-9.

Understanding patients, not just their diseases

“With more than 20% of children and young adults with ALL living more than 50 miles from a treatment center, this is a significant proportion of patients,” says co-author and pediatric hematologist-oncologist Seth Rotz, MD, of Cleveland Clinic Children’s. “Our findings underscore the importance of understanding not just the diseases of our patients, but our patients themselves. Where do they live? How far are they from the nearest pharmacy? From the nearest Emergency Department? Do they have reliable transportation and high-speed internet access? All these variables can impact the continuity and quality of care a child receives.”

“This study gives me a lot of hope,” Dr. Hanna says, “as at least part of the association with distance from treatment centers can be mitigated. Every patient who receives care for pediatric cancer at Cleveland Clinic Children’s receives a comprehensive social work consultation within 30 days of diagnosis. For those patients who live far from us, we work with local agencies to offer local accommodation for families during intense periods of treatment. We partner with transportation services to arrange for rides to clinic if needed. Importantly, we offer virtual visits when possible to answer any questions along the way and ensure adherence to treatment.”

Advertisement

Related Articles

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Squamous cell carcinoma
June 2, 2025/Cancer/News & Insight
Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit

Photonic sensor
May 22, 2025/Cancer/News & Insight
Novel Partnership Aims to Advance ctDNA Testing in Non-Small Cell Lung Cancer

Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization

gastroesophageal cancer illustration
May 20, 2025/Cancer/News & Insight
Roughly One-Third of Patients with Metastatic Gastroesophageal Cancer May be Eligible for New Targeted Therapy

Long-acting antiemetics and high-dose steroids key to minimizing acute nausea

Neoadjuvant immunotherapy
May 16, 2025/Cancer/News & Insight
Changing Course in Treating Advanced Melanoma

Neoadjuvant immunotherapy improves outcomes

Dr. Abhay Singh
May 14, 2025/Cancer
Managing Weight and Diabetes May Offer Promise for Blood Cancer Prevention (Podcast)

Use of GLP-1s and improving cardiovascular health lowers risk of hematologic malignancies

Ad